Volume 92, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Directly observed therapy short-course (DOTS) requires direct observation of tuberculosis (TB) patients and manual recording of doses taken. Programmatically, manual tracking is both time-consuming and prone to human error. Our project in western Uganda assessed the impact on TB treatment outcomes of a comprehensive patient support program including eCompliance, a biometric medical record device, with the aim of increasing TB patient retention. Through an observational study of 142 patients, DOTS outcomes of patients in the intervention group were compared with two control groups. Descriptive statistical comparisons, case-cohort analysis, and difference in change over time were used to assess the impact. Intervention patients had a higher cure rate than all other patients (55.6% versus 28.3% [ < 0.01]) and the odds of having a “cured” outcome were 3.17 higher ( < 0.05). The intervention group had a statistically significantly lower odds of having a negative outcome (0% versus.17% [ < 0.01]) than patients from the control groups. Additionally, the intervention group had a lost to follow-up rate lower than all other groups (0% versus 7%) that was trending on significant. In resource-limited settings, implementing comprehensive DOTS including may reduce the occurrence of negative DOTS outcomes for patients.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2012. Global Tuberculosis Report. Geneva, Switzerland: WHO. Available at: http://www.who.int/tb/publications/global_report/en/. Accessed June 25, 2014. [Google Scholar]
  2. Zumla A, Raviglione M, Hafner R, von Reyn CF, , 2013. Tuberculosis. N Engl J Med 368: 745755.[Crossref] [Google Scholar]
  3. Gray JM, Cohn DL, , 2013. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med 34: 3243.[Crossref] [Google Scholar]
  4. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M, , 2009. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 68: 22402246.[Crossref] [Google Scholar]
  5. Zumla A, Nahid P, Cole ST, , 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388404.[Crossref] [Google Scholar]
  6. Glaziou P, Falzon D, Floyd K, Raviglione M, , 2013. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 34: 316.[Crossref] [Google Scholar]
  7. Ben Amor Y, Day MS, Schluger NW, , 2010. Preventing the next generation of extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 14: 525527. [Google Scholar]
  8. Lienhardt C, Glaziou P, Uplekar M, Lonnroth K, Getahun H, Raviglione M, , 2012. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 10: 407416. [Google Scholar]
  9. Davies PD, , 2003. The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2: 203209.[Crossref] [Google Scholar]
  10. Operation ASHA, 2013. Technology: The eCompliance Project. Available at: http://www.opasha.org/our-work/ecompliance-innovation-and-health/. Accessed October 11, 2013. [Google Scholar]
  11. Newell JN, Baral SC, Pande SB, Bam DS, Malla P, , 2006. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomized controlled trial. Lancet 367: 903909.[Crossref] [Google Scholar]
  12. Wright J, Walley J, Philip A, Pushpananthan S, Dlamini E, Newell J, Dlamini S, , 2004. Direct observation of treatment for tuberculosis: a randomized controlled trial of community health workers versus family members. Trop Med Int Health 9: 559565.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 02 Jul 2014
  • Accepted : 31 Jan 2015
  • Published online : 03 Jun 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error